Revance has secured FDA clearance for an under-eye injectable, marking the company's expansion into a territory long dominated by Allergan's Botox and filler combinations. The approval signals the agency's willingness to clear new neuromodulator indications in a crowded market—and underscores how under-eye work, whether hollowing or dynamic lines, remains a high-volume, high-margin procedure for independent practices.
Regulatory
Revance Wins FDA Nod for Under-Eye Injectables
The neuromodulator maker gains approval for a new indication, expanding its footprint beyond toxin.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Under-eye work remains a high-volume, high-margin procedure for independent practices.
For practice owners, the real question is adoption velocity. Revance's existing market share in toxin is modest; switching costs and rebate lock-in via Allergan's Alle platform and Galderma's Aspire remain formidable. That said, practices seeking product diversification or those already stocked with Revance may find this indication useful for bundling with filler or RF microneedling protocols.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.